Alembic Pharma's JV gets USFDA's nod for Desonide Ointment | | Udaipur News | Udaipur Latest News | udaipur local news । Udaipur Updates
Home / BUSINESS / Alembic Pharma’s JV gets USFDA’s nod for Desonide Ointment

Alembic Pharma’s JV gets USFDA’s nod for Desonide Ointment

Alembic Pharmaceuticals’ joint venture (JV) Aleor Dermaceuticals (Aleor) has received approval from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Desonide Ointment, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Desonide Ointment, 0.05%, of Perrigo New York, Inc. Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Desonide Ointment, 0.05%, has an estimated market size of $13 million for twelve months ending December 2018 according to IQVIA. Alembic has a cumulative total of 105 ANDA approvals (93 final approvals and 12 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Please share this news